A Compelling 'Picks and Shovels' Play on the Future of Gene Therapy
This stock offers truly asymmetrical risk and a margin of safety that most biotech stocks lack. Here's what investors should know.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
Stocks are under pressure Monday morning, but dip buyers are stepping into several big-cap names and the Nasdaq 100 (QQQ) is only modestly lower. Market breadth is reasonably constructive with roughly 45% of stocks trading higher and the Russell 2000 down about 0.4%, as I write.
Financials are weak following President Trump’s proposal to cap credit card interest rates. Retail stocks, not surprisingly, are responding positively to that same news and are among the stronger groups Monday morning.
I was optimistic that biotechnology would perform better as the JPMorgan HealthCare Conference begins Monday. Instead, the group appears to be under pressure from selling algorithms. This looks like a classic sell-the-news reaction by computers rather than a fundamental shift. That is notable because the underlying news flow in biotech has actually been quite positive, particularly with the FDA signaling greater flexibility around certain regulatory pathways and a number of large deals.
Gene therapy stocks are getting hit along with the broader biotech complex, but much of this selling appears indiscriminate. These stocks are being sold because they sit inside pressured ETFs, not because of company-specific developments. That creates opportunity. One name I have followed for some time now offers what I believe is truly asymmetrical risk.
ClearPoint Neuro
ClearPoint Neuro (CLPT) began as a niche neurosurgical navigation company. It has since evolved into essential infrastructure for the emerging cell and gene therapy industry. Its technology is increasingly becoming the mandatory pathway for delivering life-altering therapies into the final inch of the human brain.
The company specializes in MRI-guided navigation for the brain and spine, enabling minimally invasive procedures for complex neurological disorders such as Parkinson’s disease, epilepsy, and brain tumors. By combining proprietary hardware, software, and real-time MRI imaging, ClearPoint allows surgeons to guide instruments with sub-millimeter precision.
This improves outcomes across a wide range of procedures, including deep brain stimulation, biopsies, laser ablation, and increasingly, direct gene and cell therapy delivery. What was once a single product story has become a diversified platform with multiple growth engines and meaningful regulatory tailwinds.
Four Pillars of Growth
ClearPoint’s business rests on four primary pillars that combine recurring revenue with high-margin upside tied to partner drug approvals.
1. Biologics and Drug Delivery
This is the crown jewel of the story. ClearPoint works with more than 60 pharmaceutical and biotechnology companies to enable direct delivery of experimental therapies into the brain.
When a partner therapy is approved, ClearPoint’s SmartFlow cannula is often written directly into the FDA label. That creates a mandatory revenue stream for every patient treated for the life of the drug. ClearPoint does not market to patients or physicians. Its device is part of the therapy itself.
2. Neurosurgical Navigation
ClearPoint’s MRI guided navigation systems are installed in leading academic medical centers worldwide. These placements generate recurring revenue while embedding the company deeply with neurosurgeons who often become the primary adopters of future drug delivery applications.
3. Laser Therapy and Access
The company has expanded into laser-based therapy and robotic access.
ClearPoint recently introduced robotic neuro navigation using a KUKA robotic arm to automate complex workflows. The Prism system allows surgeons to ablate diseased tissue using targeted heat. Recent FDA clearance for use with 1.5 Tesla MRI scanners significantly expands the addressable market beyond elite academic hospitals into community settings.
This segment follows a classic razor-and-blade model with recurring revenue from disposable fibers and field-based clinical specialists who support surgeons during procedures.
4. Neurocritical Care
In November 2025, ClearPoint acquired IRRAS Holdings, bringing in the IRRAflow system. IRRAflow is the first active fluid exchange platform designed to treat brain bleeds and hydrocephalus. The acquisition materially expanded ClearPoint’s commercial footprint and opened access to a global neurocritical care market estimated at roughly $500 million annually.
Avoiding the Binary Bet
What makes ClearPoint compelling relative to a typical gene therapy stock is that it is not a binary bet on a single drug. Instead, it offers stability with layered upside through multiple partners.
Key partner relationships include PTC Therapeutics (PTCT) , which already has commercial products in the market and provides a revenue foundation, uniQure (QURE) with high stakes regulatory upside in Huntington’s disease, and Aspen Neuroscience, which represents a long-term opportunity in the large Parkinson’s disease market.
The uniQure Connection and Asymmetrical Risk
ClearPoint’s most visible partnership is with uniQure and its Huntington’s disease gene therapy AMT 130. Because large molecule therapies cannot cross the blood-brain barrier, they must be delivered directly into the brain. uniQure uses ClearPoint’s system to perform these infusions under live MRI guidance, ensuring accurate placement and minimizing tissue damage.
This relationship has already demonstrated its leverage. In late 2025, when uniQure released data showing a substantial slowing of disease progression, CLPT surged sharply in a single session. When the FDA later indicated that the data might be insufficient for an immediate biologics license application, the stock retraced.
On Jan. 9, 2026, uniQure announced that it had scheduled a Type A meeting with the FDA to discuss potential accelerated approval pathways. If the FDA supports an accelerated route, procedure volume could begin ramping late in 2026. If the agency requires a more traditional Phase 3 trial, ClearPoint still benefits as the mandatory delivery partner for every enrolled patient. Importantly, the stock appears priced today for the slower and more conservative outcome.
Leadership and Financial Positioning
Aspen Neuroscience recently completed dosing in Cohort 3 of its ASPIRO trial, further validating ClearPoint’s ability to deliver cryopreserved living cells with extreme precision.
ClearPoint has also strengthened its clinical leadership by appointing Dr. Paul Larson as Chief Medical Officer. Dr. Larson is a highly respected neurosurgeon and a principal investigator in Aspen’s Parkinson’s program. Bringing that level of expertise inside the company reinforces ClearPoint’s position at the center of evolving standards of care.
From a financial perspective, management has guided to pro forma 2026 revenue of $54 million to $60 million, a meaningful increase from 2025 levels. New ICD 10 reimbursement codes that went into effect in late 2025 improve billing clarity for intracranial drug delivery and IRRAflow procedures, removing a key adoption barrier for hospitals.
The company ended the most recent quarter with approximately $38 million in cash and a reduced burn rate. Fourth-quarter revenue was preannounced at $10.4 million, up roughly 20% year over year.
Bottom Line
ClearPoint Neuro is not a drug company. It is a diversified therapy-enabling platform positioned at the intersection of neurosurgery, robotics, and gene therapy. While it remains unprofitable and dependent on partner clinical success, the picks and shovels model provides a margin of safety that most biotech stocks lack.
Whether the FDA grants uniQure an accelerated pathway or requires additional data, we believe ClearPoint’s technology remains critical to the future of neuro medicine.
I have established a core position in CLPT and intend to trade around that position as the chart develops and key catalysts approach.
At the time of publication, Rev Shark was long CLPT.
